Turning Point Therapeutics, Inc.

Turning Point Therapeutics, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2013-10-08
Employees
251
Market Cap
-
Website
http://www.tptherapeutics.com

A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

First Posted Date
2023-04-25
Last Posted Date
2023-09-26
Lead Sponsor
Turning Point Therapeutics, Inc.
Registration Number
NCT05828277
Locations
🇪🇸

Local Institution - 4103, Madrid, Spain

🇺🇸

Gabrail Cancer Research Center, Canton, Ohio, United States

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

First Posted Date
2023-04-25
Last Posted Date
2024-10-31
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT05828303
Locations
🇪🇸

Local Institution - 2138, Madrid, M, Spain

🇺🇸

Local Institution - 2102, Denver, Colorado, United States

🇺🇸

Gabrail Cancer Center Research, Canton, Ohio, United States

and more 36 locations

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

First Posted Date
2021-10-08
Last Posted Date
2024-04-02
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
9
Registration Number
NCT05071183
Locations
🇺🇸

Local Institution - 2107, Houston, Texas, United States

🇺🇸

Local Institution - 2102, Virginia Beach, Virginia, United States

🇺🇸

Local Institution - 2101, California City, California, United States

and more 3 locations

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-08-12
Last Posted Date
2024-04-17
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
17
Registration Number
NCT05001516
Locations
🇺🇸

Local Institution - 0017, Fullerton, California, United States

🇺🇸

Local Institution - 0012, Lafayette, Indiana, United States

🇺🇸

Local Institution - 0013, Duarte, California, United States

and more 4 locations

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

First Posted Date
2021-04-19
Last Posted Date
2023-05-26
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
11
Registration Number
NCT04849273
Locations
🇺🇸

Local Institution - 2103, Hackensack, New Jersey, United States

🇺🇸

Local Institution - 2102, Fairfax, Virginia, United States

🇰🇷

Local Institution - 6304, Seoul, Korea, Republic of

and more 12 locations

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

First Posted Date
2019-11-13
Last Posted Date
2024-06-13
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
41
Registration Number
NCT04161391
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Local Institution - 2120, Houston, Texas, United States

🇺🇸

Baylor College of Medicine - Baylor Heart Clinic, Houston, Texas, United States

and more 18 locations

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

First Posted Date
2019-09-19
Last Posted Date
2024-11-13
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
75
Registration Number
NCT04094610
Locations
🇬🇧

Local Institution - 4402, London, United Kingdom

🇬🇧

Local Institution - 4401, Cardiff, United Kingdom

🇺🇸

Local Institution - 2120, Orlando, Florida, United States

and more 65 locations

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

First Posted Date
2019-06-21
Last Posted Date
2024-12-20
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
95
Registration Number
NCT03993873
Locations
🇺🇸

Local Institution - 2102, La Jolla, California, United States

🇺🇸

Local Institution - 2108, Orange, California, United States

🇺🇸

Local Institution - 2105, Denver, Colorado, United States

and more 21 locations

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

First Posted Date
2017-03-28
Last Posted Date
2024-12-04
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
500
Registration Number
NCT03093116
Locations
🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 152 locations
© Copyright 2024. All Rights Reserved by MedPath